Skip to main content
TipRanks
Go Ultimate75% OFF

Neurones (NRO) AI Stock Analysis

5 Followers
FR:NRO

Neurones

(Paris:NRO)

Select Model
Rating:84Outperform
Price Target:EUR 47.00â–²(18.39% Upside)
Action:reiterated
Date:11/07/26

Neurones earns a strong overall score, primarily driven by its exceptional financial fundamentals, minimal debt, and consistent profitability. Its valuation is compelling, supported by a healthy dividend yield and a reasonable earnings multiple. While the long-term technical trend is highly bullish, investors should be aware of overbought oscillators that indicate potential short-term price consolidation.

Positive Factors
Steady Revenue and Profit GrowthSustained revenue expansion across 2020–2025, combined with solid EBIT margins and an improved net margin, indicates durable demand for Neurones’ consulting and IT services. This growth provides a broader base for recurring client work and supports continued investment in specialist capabilities.
Negative Factors
Gross-Margin VolatilityLarge gross-margin swings make it harder to assess the underlying durability of reported profitability. They may reflect changes in cost mix or classification and create uncertainty about how consistently revenue growth will translate into gross profit, even though EBIT and net margins remain positive.

Neurones (NRO) vs. iShares MSCI France ETF (EWQ)

-25%-20%-15%-10%-5%0%5%10%15%FR:NRO-2.82%EWQ+2.84%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 967.42M
Dividend Yield
3.53%
Average Volume (3M)
6,433
Price to Earnings (P/E)
17.4
Beta (1Y)
0.41
Revenue Growth
6.68%
EPS Growth
9.16%
Country
France
Employees
7,329
Sector
General
Sector Strength
55
Industry
Information Technology Services

Neurones Business Overview & Revenue Model

Company Description

Neurones S.A., an information technology (IT) services provider founded in 1984 and headquartered in Nanterre, France, operates with a global reach. The company delivers a broad spectrum of services encompassing infrastructure, application developmen...

How the Company Makes Money

Neurones makes money primarily by selling professional services to business and public-sector clients under consulting and IT services engagements. Revenue is mainly generated from (1) time-and-materials consulting and engineering assignments billed...

Neurones Financial Statement Overview

Summary

Neurones presents a stellar financial profile characterized by consistent top-line growth, an unleveraged balance sheet with a low debt-to-equity ratio of 0.09, and robust free cash flow generation. The score is marginally held back by a slight recent contraction in EBITDA margins.

Income Statement

82Very Positive

Balance Sheet

92Very Positive

Cash Flow

86Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue887.74M857.20M810.40M741.17M665.38M579.88M
Gross Profit504.95M90.04M388.76M346.76M81.64M69.73M
EBITDA96.35M90.32M95.56M96.63M88.72M76.33M
Net Income55.29M52.07M52.50M49.41M44.24M37.71M
Balance Sheet
Total Assets730.02M749.03M725.69M674.25M616.22M567.82M
Cash, Cash Equivalents and Short-Term Investments301.88M340.78M326.49M297.76M272.06M265.17M
Total Debt41.30M36.96M42.02M43.98M35.57M35.32M
Total Liabilities296.68M284.16M289.52M266.34M240.63M214.90M
Stockholders Equity376.16M399.98M378.10M354.39M330.58M311.56M
Cash Flow
Free Cash Flow88.59M70.33M72.34M54.09M44.33M58.10M
Operating Cash Flow100.76M80.77M84.38M72.08M54.94M64.68M
Investing Cash Flow-23.85M-21.16M-19.69M-21.57M-12.26M-10.62M
Financing Cash Flow-67.63M-45.11M-34.48M-27.06M-36.08M-55.42M

Neurones Technical Analysis

Technical Analysis SentimentPositive
Last Price39.70

Price Trends

50DMA37.32Positive
100DMA37.08Positive
200DMA36.04Positive

Market Momentum

MACD1.08Negative
RSI57.10Neutral
STOCH65.48Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:NRO, the sentiment is Positive. The current price of 39.70 is above the 20-day moving average (MA) of 38.90, above the 50-day MA of 37.32, and above the 200-day MA of 36.04, indicating a bullish trend. The MACD of 1.08 indicates Negative momentum. The RSI at 57.10 is Neutral, neither overbought nor oversold. The STOCH value of 65.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:NRO.

Neurones Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

FR:NRO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:NROFR:NRO84OutperformEUR 946.55M17.4114.25%3.53%6.68%9.16%
FR:WAVEFR:WAVE83OutperformEUR 851.85M10.3112.19%1.45%1.13%8.32%
FR:SOPFR:SOP72OutperformEUR 3.65B12.2614.45%2.78%1.62%12.95%
FR:CAPFR:CAP67NeutralEUR 20.45B14.8011.82%2.82%6.23%-11.48%
FR:ATEFR:ATE66NeutralEUR 2.94B20.736.19%1.79%0.11%-6.28%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
FR:ATOFR:ATO39UnderperformEUR 443.04M-0.37117.34%―-14.39%-173.10%

* General Sector Average

Performance Comparison

-50%-25%0%25%50%FR:NROFR:ATEFR:ATOFR:CAPFR:SOPFR:WAVEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:NRO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:NRONeurones39.70-1.20-2.93%
FR:ATEALTEN83.9521.2333.84%
FR:ATOAtos SE22.24-20.36-47.79%
FR:CAPCapgemini120.65-2.44-1.98%
FR:SOPSopra Steria190.7066.2853.28%
FR:WAVEWavestone SA34.45-12.93-27.29%

Neurones Corporate Events

NEURONES Reports 7.1% Organic Growth in Third Quarter

Nov 4, 2026

NEURONES is a French management consulting and digital services company that helps major organizations deliver digital projects, transform IT infrastructures and accelerate AI adoption. Its activities include data and AI, digital projects, IT service...

Neurones Releases Half-Year Financial Report for First Half of 2026

Sep 16, 2026

Neurones has published its half-year financial report for the period ending 30 June 2026, providing stakeholders with an overview of its activity, consolidated financial statements and related certifications.The release highlights that the report inc...

Neurones Delivers Strong First-Half 2026 Growth and Reaffirms Margin Guidance

Sep 9, 2026

Neurones reported first-half 2026 revenues of €454.8 million, up 7.2% year-on-year, driven largely by 6.9% organic growth and confirming its momentum in digital consulting and IT services. Operating profit rose 19.9% to represent 8.7% of revenue, whi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026